• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Contents
3. Contents: nucleic acid basics
4. RNA vs. DNA
5. Cytosine deamination
6. Contents: nucleic acid cytosine deaminases
7. Human AID/APOBEC family mermbers
8. AID/APOBEC family members in vertebrates
9. Are all AID/APOBECs DNA mutators?
10. Effect of expressing some APOBECs in E.coli
11. Hottest spots for deamination in E.coli apoB
12. Contents: retrovirus restriction
13. Human cells contain anti-retroviral factor
14. Model for HIV restriction by APOBEC3G (A3G)
15. GFP-based assay for retroviral infectivity
16. APOBEC3G inhibits retroviral infection
17. Retroviral restriction by A3G and A3F
18. Strand-specific retroviral hypermutation
19. Cumulative effect of A3F and A3G
20. A3G and A3F are broadly (co-) expressed
21. HIV vif counteracts A3G > A3F
22. Mechanism of A3G inhibition by HIV-1 Vif
23. Model for retroelement restriction
24. Summary of part 3
25. Contents: endogenous retroelement restriction
26. Human APOBEC family members- A3G and A3F
27. Alternative APOBEC3 (A3) function?
28. Effect of APOBECs on endogenous retroelements
29. Can APOBEC3 inhibit yeast Ty1?
30. Ty1 retrotransposition assay
31. A3G and A3F inhibit Ty1 retrotransposition
32. How do A3G and A3F restrict Ty1?
33. Human A3s inhibit Ty1 and other retroelements
34. Summary of part 4
35. Contents: non-LTR retroelement restriction
36. Human APOBEC family members - Apobec3
37. Differential localization of human A3s
38. Transposable elements in the human genome
39. Replication strategies of L1 and LTR-retroelements
40. LINEs replication
41. L1s destabilize genomes and cause disease
42. L1 transposition assay
43. Can A3B inhibit L1 retrotransposition?
44. A3B and A3F inhibit L1 retrotransposition (1)
45. A3B and A3F inhibit L1 retrotransposition (2)
46. HIV restriction by HA-tagged constructs
47. A3B deaminase activity is not required
48. Retrotransposed L1 DNA accumulation
49. Model for how A3F & A3B inhibit L1 transposition
50. Residues 65-190 of A3F & A3B are 96% identical
51. A3F appears strongly expressed in human testes
52. A3 inhibits transposable elements in human
53. Summary of part 5
54. Contents: a unifying hypothesis
55. The hyphothesis and evidence supporting it
56. Acknowledgements

Topics Covered

• Nucleic acid basics
• AID-related APOBEC3 proteins are DNA cytosine deaminases
• Retrovirus (e.g. HIV and MLV) restriction by APOBEC3 proteins
• Endogenous retroelement (e.g. Ty1 and L1) restriction by APOBEC3 proteins
• Multifunctionality of AID in diversifying antibody genes and in restricting retroelements

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Prof. Reuben Harris has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.